Ann L.B. Seynhaeve

Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.

Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats.

Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.

Vasoactive peptides upregulate mRNA expression and secretion of vascular endothelial growth factor in human airway smooth muscle cells.

Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response.

TNF and manipulation of the tumor cell-stromal interface: "ways to make chemotherapy effective".

Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.

Angiogenic capacity of human adipose-derived stromal cells during adipogenic differentiation: an in vitro study.

Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imaging.

Exposing endothelial cells to tumor necrosis factor-α and peripheral blood mononuclear cells damage endothelial integrity via interleukin-1ß by degradation of vascular endothelial-cadherin.

Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes.

Enhanced Specificity and Drug Delivery in Tumors by cRGD-Anchoring Thermosensitive Liposomes.

Formulation and optimization of idarubicin thermosensitive liposomes provides ultrafast triggered release at mild hyperthermia and improves tumor response.

Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades.

High-Resolution Intravital Microscopy of Tumor Angiogenesis.